BridgeBio Pharma, Inc. (BBIO) stock
BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$78.17−1.37 (-1.72%)
Close on Nov 12, 2026Market cap $15.23BP/E –Yield –
BridgeBio Pharma gross margin
Gross margin is gross profit as a percentage of revenue.
BridgeBio Pharma's gross margin for the twelve months ending Sep 30, 2026 was 94.3%. For fiscal 2025 it was 95.8%, against 98.3% the year before. The highest annual figure on record is 98.3% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95.8% | −2.4 |
| FY2024 | Dec 31, 2024 | 98.3% | +24.5 |
| FY2023 | Dec 31, 2023 | 73.7% | −21.9 |
| FY2022 | Dec 31, 2022 | 95.6% | +0.0 |
| FY2021 | Dec 31, 2021 | 95.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 94.2% | −0.4 |
| Q2 FY2026 | Jun 30, 2026 | 93.8% | −2.9 |
| Q1 FY2026 | Mar 31, 2026 | 94.9% | −2.8 |
| Q4 FY2025 | Dec 31, 2025 | 94.7% | +30.2 |
| Q3 FY2025 | Sep 30, 2025 | 94.6% | +16.5 |
| Q2 FY2025 | Jun 30, 2025 | 96.7% | +24.3 |
| Q1 FY2025 | Mar 31, 2025 | 97.7% | −2.0 |
| Q4 FY2024 | Dec 31, 2024 | 64.6% | −1.2 |
| Q3 FY2024 | Sep 30, 2024 | 78.1% | −7.3 |
| Q2 FY2024 | Jun 30, 2024 | 72.4% | +8.9 |
| Q1 FY2024 | Mar 31, 2024 | 99.7% | +35.4 |
| Q4 FY2023 | Dec 31, 2023 | 65.7% | +0.3 |
| Q3 FY2023 | Sep 30, 2023 | 85.4% | +204.0 |
| Q2 FY2023 | Jun 30, 2023 | 63.5% | −35.6 |
| Q1 FY2023 | Mar 31, 2023 | 64.3% | −23.6 |
| Q4 FY2022 | Dec 31, 2022 | 65.4% | +27.4 |
| Q3 FY2022 | Sep 30, 2022 | -118.6% | −218.4 |
| Q2 FY2022 | Jun 30, 2022 | 99.1% | −0.9 |
| Q4 FY2021 | Dec 31, 2021 | 88.0% | – |
| Q3 FY2021 | Sep 30, 2021 | 38.0% | – |
| Q2 FY2021 | Jun 30, 2021 | 99.8% | – |
| Q3 FY2020 | Sep 30, 2020 | 100.0% | – |
See a number that looks wrong?